Metadata governance in life sciences is now a regulatory control

At a glance

What this is: This is an analysis of why metadata governance is a regulatory control in life sciences, with the key finding that data integrity depends on surrounding context, not just the dataset itself.

Why it matters: It matters because IAM, governance and risk teams must treat provenance, lineage and stewardship as enforceable controls across human, NHI and platform workflows, not as optional documentation.

By the numbers:

• Only 5.7% of organisations have full visibility into their service accounts.
• 96% of organisations store secrets outside of secrets managers in vulnerable locations including code, config files, and CI/CD tools.
• 90% of IT leaders say properly managing NHIs is essential for a successful zero-trust implementation.

👉 Read Collibra's analysis of metadata governance in life sciences

Context

In life sciences, metadata is the record of who touched a result, when it was captured, on which system it was created and whether that record has remained intact. That is what makes clinical evidence attributable and defensible under FDA and GCP scrutiny, and it is why metadata governance belongs inside the identity and access model, not beside it.

The problem is that many organisations still treat metadata as an administrative layer rather than as evidence of chain of custody. Once lineage, timestamps, ownership and alteration history are fragmented across systems, the regulator sees uncertainty where the organisation sees a dataset.

That same governance pattern appears across human, machine and platform identities: if the record of access, action and change is incomplete, trust collapses even when the underlying data looks strong. For life sciences teams, this is a governance problem first and a technology problem second.

Key questions

Q: How should life sciences teams govern metadata for regulated submissions?

A: They should treat metadata as regulated evidence, not administrative detail. Start by defining the minimum proof set for each record, then capture it automatically at the point of creation. Link source, timestamp, system identity and change history to one governed workflow so auditors can reconstruct custody without manual intervention.

Q: Why does metadata matter as much as the data itself in pharma and biotech?

A: Because the regulator is not only judging what the numbers say. It is judging whether the organisation can prove who created them, when they were created, and whether they were altered. Without that context, even accurate data becomes difficult to defend under review.

Q: What breaks when clinical data has weak lineage and audit trails?

A: The organisation loses evidentiary continuity. Reviewers can no longer prove that the result came from a validated system, remained unchanged, or reflects the original event. That creates submission delays, more regulatory questions, and in some cases a complete response letter.

Q: Who should own metadata governance in regulated life sciences programmes?

A: Ownership should sit with a named business steward and a technical steward, because metadata is both operational and evidentiary. The business owner defines what must be proven, while the technical owner ensures those fields are captured, protected and auditable across the lifecycle.

Technical breakdown

Audit trails and lineage are the trust layer for clinical data

Audit trails show what happened to a record, while lineage shows where it came from and how it changed over time. In regulated environments, those two functions work together to make data attributable, contemporaneous and original. If a clinical result can be moved between tools, edited without trace, or submitted without clear source context, the dataset loses evidentiary value even if the numbers are correct. Metadata therefore behaves like a security control for scientific truth, not just a reporting feature.

Practical implication: verify that every regulated dataset can prove source, timestamp, change history and system of record without manual reconstruction.

Validation depends on system identity as much as data integrity

A validated system is not just one that stores data correctly. It is one whose identity, configuration and access path are known well enough that the record can be trusted across collection, review and submission. If a system cannot show who accessed it, which process wrote the record, and whether the environment stayed within validated bounds, metadata becomes the evidence that the system is still controlled. That is why system identifiers and access records belong in the same governance conversation as clinical quality.

Practical implication: tie metadata controls to validated system boundaries, not to storage locations alone.

ALCOA+ is a metadata standard disguised as compliance language

ALCOA+ works because each principle depends on metadata that can be captured and defended. Attributable needs identity. Contemporaneous needs timestamps. Original needs source lineage. Accurate needs change control and reconciliation. When any of those fields is missing or inconsistent, compliance issues become provenance issues. The real test is not whether data exists, but whether the organisation can reconstruct the full record of collection and handling without guesswork.

Practical implication: treat ALCOA+ gaps as governance failures in record provenance, not as isolated documentation defects.

Breaches seen in the wild

• Cisco DevHub NHI breach — IntelBroker exploited exposed Cisco credentials, API tokens and keys in DevHub.
• Salt Typhoon US telecoms breach — Salt Typhoon APT used stolen credentials and Cisco CVE to breach US telecoms.

Read our 52 NHI Breaches Analysis report for a comprehensive view of breaches impacting Non-Human Identities including AI Agents.

NHI Mgmt Group analysis

Metadata governance is the control plane for regulated evidence. In life sciences, the question is not whether the dataset contains the right numbers but whether the organisation can prove where those numbers came from and who touched them. FDA 21 CFR Part 11 and ALCOA+ both reflect the same underlying governance requirement: data must remain attributable across its full lifecycle. Practitioners should treat metadata as the proof layer for regulated identity and access, not as an administrative afterthought.

Context collapse is the failure mode that turns usable data into unusable evidence. When timestamps, system identifiers, reviewer identities and alteration history sit in separate tools, the organisation loses the ability to defend continuity of custody. That is not merely a data management issue. It is the point at which a regulator can question whether the record still represents the original clinical event. The implication is that provenance must be governed as a single trust chain, not as disconnected fields.

Life sciences metadata exposes the same governance weakness seen in NHI environments: weak ownership makes trust brittle. If no one can answer who owns the metadata, who validates it and who can alter it, the organisation has the same problem it has with unmanaged service accounts. The control gap is not just technical capture but stewardship. Practitioners should define metadata ownership with the same discipline used for privileged identity governance.

ALCOA+ is most effective when it is operationalised as evidence lifecycle governance. The principles only hold if collection, review, retention and change control are enforced as repeatable processes. That aligns well with NIST CSF and records management thinking, because trust degrades when evidence is treated as static content rather than a governed asset. Life sciences teams should therefore manage metadata as a regulated identity surface across submission, audit and post-market review.

Metadata failures are not isolated quality defects; they are approval-risk multipliers. When record context cannot be reconstructed, every downstream review takes longer and every challenge becomes harder to answer. That compounds across trial operations, regulatory submission and dispute response. Practitioners should assume that incomplete provenance will be interpreted as incomplete control.

From our research:

• Only 5.7% of organisations have full visibility into their service accounts, according to Ultimate Guide to NHIs , Key Research and Survey Results.
• 96% of organisations store secrets outside of secrets managers in vulnerable locations including code, config files, and CI/CD tools.
• Forward-looking control gap: The same visibility problem that affects service accounts also affects evidence workflows when metadata owners, system logs and change records are scattered across tools, so teams should explore the Ultimate Guide to NHIs , Key Research and Survey Results for the governance baseline and the NIST SP 800-63 Digital Identity Guidelines for identity assurance concepts that support traceable control.

What this signals

Metadata governance is becoming an identity-adjacent control problem, not just a records problem. Once regulated evidence is spread across collection tools, validation platforms and review workflows, the organisation needs stronger lineage discipline than most data programmes currently maintain. The practical shift is toward proving provenance continuously, not only at submission time.

Only 96% of organisations store secrets outside of secrets managers in vulnerable locations including code, config files, and CI/CD tools. That figure matters here because provenance breaks the same way secrets governance does. When control points are scattered, the organisation can no longer show who had access, who changed what, and whether the record remained within a trusted boundary.

ALCOA+ should be treated as a living governance standard, not a compliance checklist. Life sciences teams that want faster review cycles and fewer regulatory queries will need evidence workflows that are machine-readable, reviewable and owned end to end. The organisations that do this well will be able to defend not just data accuracy, but data trustworthiness.

For practitioners

• Map regulated data to its proof trail Define the minimum metadata set for each clinical or research record, including source, timestamp, system of origin, editor identity and change history. Make the required fields part of the workflow so that provenance is captured at creation rather than reconstructed later.
• Tie metadata stewardship to named owners Assign a business owner and technical steward for each critical metadata domain, with explicit responsibility for validation, exception handling and retention. That ownership should be reviewed alongside the underlying dataset, not treated as a separate administrative task.
• Align access controls with validated system boundaries Review whether the systems that generate or transform regulated data are themselves inside approved access, logging and change-control boundaries. If a system can alter evidence without a corresponding audit trail, the metadata chain is already compromised.
• Use review cycles to test evidentiary completeness Sample submissions, adverse-event records and trial outputs to verify that the organisation can reconstruct provenance without spreadsheets or local knowledge. Where manual reconstruction is needed, treat that as a governance defect and remediate the process.

Key takeaways

• Metadata is the evidence layer that makes life sciences data defensible under regulatory review.
• When lineage, timestamps and ownership are fragmented, the organisation loses the ability to prove chain of custody even if the dataset is technically correct.
• Teams should govern metadata as a regulated identity surface, with named ownership, automated capture and auditable change control.

Key terms

• Metadata Governance: Metadata governance is the discipline of defining, capturing and protecting the information that proves where a record came from and how it changed. In regulated life sciences, it turns data into evidence by making lineage, ownership, timestamps and alteration history consistently auditable across systems.
• Chain Of Custody: Chain of custody is the documented history of a record from creation through every handoff, review and change. In a regulated environment, it is the proof that data remained traceable, controlled and attributable, so reviewers can trust the record without reconstructing its history from memory or spreadsheets.
• ALCOA+: ALCOA+ is a set of evidence principles for regulated data: attributable, legible, contemporaneous, original and accurate, with completeness, consistency, enduring and available often added. It is effectively a metadata requirement because each principle depends on identity, timestamp, lineage and change control being available for review.
• Lineage: Lineage is the path a data record follows from source to output, including systems, transformations and owners. It matters because a record can only be trusted when the organisation can show how it was produced and whether every change stayed inside approved control boundaries.

Deepen your knowledge

Metadata governance in regulated environments is covered in the NHI Foundation Level course, the industry's only accredited NHI security programme. If your team is trying to prove trust in records, lineage and stewardship across systems, that course provides a practical starting point.

This post draws on content published by Collibra: metadata governance in life sciences and why it underpins data trust. Read the original.